Combined Chondroitin sulfate and Glucosamine is more efficient than Celebrex in reducing serum levels of COLL2-1, a cartilage degradation biomarker, in patients with severe OA: results from a randomized, double-blind, multicentric clinical trial
The objective of the study was to investigate soluble osteoarthritis (OA) biomarkers in the patients of the double-blind Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) comparing the symptomatic efficacy and safety of Chondroitin Sulfate (CS)+Glucosamine Hydrochloride (GH) versus...
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2015-08, Vol.37 (8), p.e121-e122 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e122 |
|---|---|
| container_issue | 8 |
| container_start_page | e121 |
| container_title | Clinical therapeutics |
| container_volume | 37 |
| creator | Henrotin, Y Arden, N Berenbaum, F Blanco, F.J Castillo, J.R Conaghan, P.G Hick, A.C Hochberg, M.C Martel-Pelletier, J Monfort, J Möller, I Pap, T Pelletier, J.-P Richette, P Sawitzke, A.D du Souich, P |
| description | The objective of the study was to investigate soluble osteoarthritis (OA) biomarkers in the patients of the double-blind Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) comparing the symptomatic efficacy and safety of Chondroitin Sulfate (CS)+Glucosamine Hydrochloride (GH) versus CElecoxib (CE) in knee OA patients. |
| doi_str_mv | 10.1016/j.clinthera.2015.05.347 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1693873808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0149291815006542</els_id><sourcerecordid>3735386301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1898-d62756ecc8d56ed22995463d5abd9d9d2a745bff76a2297bedd9e0501de220a73</originalsourceid><addsrcrecordid>eNqNUl2rEzEQXUTBevU3OOBrtybZbx-EsuhVKPRBBd9CNplt05vd1GS3ev3fvjtL_QCfJA_DTGbOGc6ZJHnO2YYzXr48bbSz43TEoDaC8WLDik2WVw-SFa-rJuU8__wwWTGeN6loeP04eRLjiTGWNYVYJT9aP3R2RAPt0Y8meDvZEeLsejUhqNHArZu1j2qgJrARBh8QsO-ttjhOMB3VCC067AJ-AxoNaGZtxwNEDPMADi_oIvge2v1uJ1K-BgVahck6dUAweAjKqMn6ETrrBxXuMKwXnDMViSDCVzsdCeyCxLvfviIC2o7qffADYQXa0Q_2O5o1GD93DtOO9KBsoDarCSNYDYtGVisHlCn3NHnUKxfx2a94k3x6--Zj-y7d7W_ft9tdqnnd1KkpRVWUqHVtKBghmqbIy8wUqjMNPaGqvOj6vioV_VUdGtMgKxg3KARTVXaTvLjinoP_MmOc5MnPYSRKycsmq6usZjV1VdcuHXyMAXt5DpakuJecycVjeZJ_PJaLx5IVkjymye11kjTGi8Ug42KLRmMD6kkab_8D4_U_GL-1usN7jH8XllFIJj8sl7QcEi8YK4tcZD8BUOXOtw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1693873808</pqid></control><display><type>article</type><title>Combined Chondroitin sulfate and Glucosamine is more efficient than Celebrex in reducing serum levels of COLL2-1, a cartilage degradation biomarker, in patients with severe OA: results from a randomized, double-blind, multicentric clinical trial</title><source>Elsevier ScienceDirect Journals</source><creator>Henrotin, Y ; Arden, N ; Berenbaum, F ; Blanco, F.J ; Castillo, J.R ; Conaghan, P.G ; Hick, A.C ; Hochberg, M.C ; Martel-Pelletier, J ; Monfort, J ; Möller, I ; Pap, T ; Pelletier, J.-P ; Richette, P ; Sawitzke, A.D ; du Souich, P</creator><creatorcontrib>Henrotin, Y ; Arden, N ; Berenbaum, F ; Blanco, F.J ; Castillo, J.R ; Conaghan, P.G ; Hick, A.C ; Hochberg, M.C ; Martel-Pelletier, J ; Monfort, J ; Möller, I ; Pap, T ; Pelletier, J.-P ; Richette, P ; Sawitzke, A.D ; du Souich, P ; for the MOVES Investigation Group</creatorcontrib><description>The objective of the study was to investigate soluble osteoarthritis (OA) biomarkers in the patients of the double-blind Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) comparing the symptomatic efficacy and safety of Chondroitin Sulfate (CS)+Glucosamine Hydrochloride (GH) versus CElecoxib (CE) in knee OA patients.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2015.05.347</identifier><language>eng</language><publisher>Bridgewater: Elsevier Inc</publisher><subject>Biomarkers ; Chondroitin sulfate ; Internal Medicine ; Medical Education</subject><ispartof>Clinical therapeutics, 2015-08, Vol.37 (8), p.e121-e122</ispartof><rights>2015</rights><rights>Copyright Elsevier Limited Aug 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291815006542$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids></links><search><creatorcontrib>Henrotin, Y</creatorcontrib><creatorcontrib>Arden, N</creatorcontrib><creatorcontrib>Berenbaum, F</creatorcontrib><creatorcontrib>Blanco, F.J</creatorcontrib><creatorcontrib>Castillo, J.R</creatorcontrib><creatorcontrib>Conaghan, P.G</creatorcontrib><creatorcontrib>Hick, A.C</creatorcontrib><creatorcontrib>Hochberg, M.C</creatorcontrib><creatorcontrib>Martel-Pelletier, J</creatorcontrib><creatorcontrib>Monfort, J</creatorcontrib><creatorcontrib>Möller, I</creatorcontrib><creatorcontrib>Pap, T</creatorcontrib><creatorcontrib>Pelletier, J.-P</creatorcontrib><creatorcontrib>Richette, P</creatorcontrib><creatorcontrib>Sawitzke, A.D</creatorcontrib><creatorcontrib>du Souich, P</creatorcontrib><creatorcontrib>for the MOVES Investigation Group</creatorcontrib><title>Combined Chondroitin sulfate and Glucosamine is more efficient than Celebrex in reducing serum levels of COLL2-1, a cartilage degradation biomarker, in patients with severe OA: results from a randomized, double-blind, multicentric clinical trial</title><title>Clinical therapeutics</title><description>The objective of the study was to investigate soluble osteoarthritis (OA) biomarkers in the patients of the double-blind Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) comparing the symptomatic efficacy and safety of Chondroitin Sulfate (CS)+Glucosamine Hydrochloride (GH) versus CElecoxib (CE) in knee OA patients.</description><subject>Biomarkers</subject><subject>Chondroitin sulfate</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNUl2rEzEQXUTBevU3OOBrtybZbx-EsuhVKPRBBd9CNplt05vd1GS3ev3fvjtL_QCfJA_DTGbOGc6ZJHnO2YYzXr48bbSz43TEoDaC8WLDik2WVw-SFa-rJuU8__wwWTGeN6loeP04eRLjiTGWNYVYJT9aP3R2RAPt0Y8meDvZEeLsejUhqNHArZu1j2qgJrARBh8QsO-ttjhOMB3VCC067AJ-AxoNaGZtxwNEDPMADi_oIvge2v1uJ1K-BgVahck6dUAweAjKqMn6ETrrBxXuMKwXnDMViSDCVzsdCeyCxLvfviIC2o7qffADYQXa0Q_2O5o1GD93DtOO9KBsoDarCSNYDYtGVisHlCn3NHnUKxfx2a94k3x6--Zj-y7d7W_ft9tdqnnd1KkpRVWUqHVtKBghmqbIy8wUqjMNPaGqvOj6vioV_VUdGtMgKxg3KARTVXaTvLjinoP_MmOc5MnPYSRKycsmq6usZjV1VdcuHXyMAXt5DpakuJecycVjeZJ_PJaLx5IVkjymye11kjTGi8Ug42KLRmMD6kkab_8D4_U_GL-1usN7jH8XllFIJj8sl7QcEi8YK4tcZD8BUOXOtw</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Henrotin, Y</creator><creator>Arden, N</creator><creator>Berenbaum, F</creator><creator>Blanco, F.J</creator><creator>Castillo, J.R</creator><creator>Conaghan, P.G</creator><creator>Hick, A.C</creator><creator>Hochberg, M.C</creator><creator>Martel-Pelletier, J</creator><creator>Monfort, J</creator><creator>Möller, I</creator><creator>Pap, T</creator><creator>Pelletier, J.-P</creator><creator>Richette, P</creator><creator>Sawitzke, A.D</creator><creator>du Souich, P</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20150801</creationdate><title>Combined Chondroitin sulfate and Glucosamine is more efficient than Celebrex in reducing serum levels of COLL2-1, a cartilage degradation biomarker, in patients with severe OA: results from a randomized, double-blind, multicentric clinical trial</title><author>Henrotin, Y ; Arden, N ; Berenbaum, F ; Blanco, F.J ; Castillo, J.R ; Conaghan, P.G ; Hick, A.C ; Hochberg, M.C ; Martel-Pelletier, J ; Monfort, J ; Möller, I ; Pap, T ; Pelletier, J.-P ; Richette, P ; Sawitzke, A.D ; du Souich, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1898-d62756ecc8d56ed22995463d5abd9d9d2a745bff76a2297bedd9e0501de220a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Biomarkers</topic><topic>Chondroitin sulfate</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henrotin, Y</creatorcontrib><creatorcontrib>Arden, N</creatorcontrib><creatorcontrib>Berenbaum, F</creatorcontrib><creatorcontrib>Blanco, F.J</creatorcontrib><creatorcontrib>Castillo, J.R</creatorcontrib><creatorcontrib>Conaghan, P.G</creatorcontrib><creatorcontrib>Hick, A.C</creatorcontrib><creatorcontrib>Hochberg, M.C</creatorcontrib><creatorcontrib>Martel-Pelletier, J</creatorcontrib><creatorcontrib>Monfort, J</creatorcontrib><creatorcontrib>Möller, I</creatorcontrib><creatorcontrib>Pap, T</creatorcontrib><creatorcontrib>Pelletier, J.-P</creatorcontrib><creatorcontrib>Richette, P</creatorcontrib><creatorcontrib>Sawitzke, A.D</creatorcontrib><creatorcontrib>du Souich, P</creatorcontrib><creatorcontrib>for the MOVES Investigation Group</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henrotin, Y</au><au>Arden, N</au><au>Berenbaum, F</au><au>Blanco, F.J</au><au>Castillo, J.R</au><au>Conaghan, P.G</au><au>Hick, A.C</au><au>Hochberg, M.C</au><au>Martel-Pelletier, J</au><au>Monfort, J</au><au>Möller, I</au><au>Pap, T</au><au>Pelletier, J.-P</au><au>Richette, P</au><au>Sawitzke, A.D</au><au>du Souich, P</au><aucorp>for the MOVES Investigation Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined Chondroitin sulfate and Glucosamine is more efficient than Celebrex in reducing serum levels of COLL2-1, a cartilage degradation biomarker, in patients with severe OA: results from a randomized, double-blind, multicentric clinical trial</atitle><jtitle>Clinical therapeutics</jtitle><date>2015-08-01</date><risdate>2015</risdate><volume>37</volume><issue>8</issue><spage>e121</spage><epage>e122</epage><pages>e121-e122</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>The objective of the study was to investigate soluble osteoarthritis (OA) biomarkers in the patients of the double-blind Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) comparing the symptomatic efficacy and safety of Chondroitin Sulfate (CS)+Glucosamine Hydrochloride (GH) versus CElecoxib (CE) in knee OA patients.</abstract><cop>Bridgewater</cop><pub>Elsevier Inc</pub><doi>10.1016/j.clinthera.2015.05.347</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2015-08, Vol.37 (8), p.e121-e122 |
| issn | 0149-2918 1879-114X |
| language | eng |
| recordid | cdi_proquest_journals_1693873808 |
| source | Elsevier ScienceDirect Journals |
| subjects | Biomarkers Chondroitin sulfate Internal Medicine Medical Education |
| title | Combined Chondroitin sulfate and Glucosamine is more efficient than Celebrex in reducing serum levels of COLL2-1, a cartilage degradation biomarker, in patients with severe OA: results from a randomized, double-blind, multicentric clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A13%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20Chondroitin%20sulfate%20and%20Glucosamine%20is%20more%20efficient%20than%20Celebrex%20in%20reducing%20serum%20levels%20of%20COLL2-1,%20a%20cartilage%20degradation%20biomarker,%20in%20patients%20with%20severe%20OA:%20results%20from%20a%20randomized,%20double-blind,%20multicentric%20clinical%20trial&rft.jtitle=Clinical%20therapeutics&rft.au=Henrotin,%20Y&rft.aucorp=for%20the%20MOVES%20Investigation%20Group&rft.date=2015-08-01&rft.volume=37&rft.issue=8&rft.spage=e121&rft.epage=e122&rft.pages=e121-e122&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2015.05.347&rft_dat=%3Cproquest_cross%3E3735386301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1693873808&rft_id=info:pmid/&rft_els_id=1_s2_0_S0149291815006542&rfr_iscdi=true |